Acazicolcept

DB18410InvestigationalProtein Based Therapies

Acazicolcept: Overview.

Mechanism: Pharmacologically active on T-cell-specific surface glycoprotein CD28 and Inducible T-cell costimulator
Curator reviewed
Also known as: 1-122-INDUCIBLE COSTIMULATORY LIGAND PROTEIN (52-HISTIDINE,57-TYROSINE,100-ARGININE) (HUMAN) FUSION PROTEIN WITH SYNTHETIC PEPTIDE LINKER (GGGGSGGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C REGION VARIANT C-TERMINAL FRAGMENT), DIMER · Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways · HUMAN INDUCIBLE T-CELL CO-STIMULATOR LIGAND (ICOS LIGAND) N-TERMINAL FRAGMENT (1-122) (VARIANT (N52>H, N57>Y, Q100>R), FUSED VIA PEPTIDYL LINKER 123GGGGSGGGGS132 TO A HUMAN IMMUNOGLOBULIN G1 FC FRAGMENT (133-363) VARIANT (C137>S, L151>A, L152>E, G154>A,
Code names: ALPN-101

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Acazicolcept, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.